2. Signaling Pathways
  3. Immunology/Inflammation
  4. Thrombopoietin Receptor
  5. Thrombopoietin Receptor Activator

Thrombopoietin Receptor Activator

Thrombopoietin Receptor Activators (3):

Cat. No. Product Name Effect Purity
  • HY-P11205A
    Cys-PKHB1 TFA
    		Activator 99.43%
    Cys-PKHB1 (Cys-txCD47) TFA is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
  • HY-P11205
    Cys-PKHB1
    		Activator
    Cys-PKHB1 (Cys-txCD47) is a peptide conjugated to PKHB1, a CD47 agonist peptide and a thrombospondin-1 peptide mimic with antitumor effects. PKHB1 induces mitochondrial alterations, ROS generation, intracellular Ca+ accumulation, and calcium-dependent cell death in breast cancer cells. PKHB1 induces immune system activation in breast cancer cells through immunogenic cell death.
  • HY-P10371
    PKHB1
    		Activator
    PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8+ T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia.